GlycoMimetics announced that the European Medicines Agency has granted orphan drug designation for GMI-1070 for the treatment of vaso-occlusive crisis in patients with sickle cell disease. GMI-1070, which has previously received both orphan drug and fast track status for VOC from the U.S. Food & Drug Administration, is being developed in partnership with Pfizer. Pfizer is responsible for the next steps of clinical development for GMI-1070.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- European Medicines Agency
- orphan drug designation